In 2017, regorafenib, an oral agent with action against VEGF signaling, obtained FDA approval for the treatment of patients with advanced HCC after progression on sorafenib.13 In the first‐line setting, FDA approval was recently obtained for the oral multikinase inhibitor lenvatinib after a phase III trial demonstrated noninferiority as compared to sorafenib. Here, VEGFA is linked to hepatocellular carcinoma.